Compare WSM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSM | MRNA |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3B | 21.5B |
| IPO Year | 1995 | 2018 |
| Metric | WSM | MRNA |
|---|---|---|
| Price | $180.56 | $44.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | ★ $209.71 | $34.27 |
| AVG Volume (30 Days) | 860.9K | ★ 4.9M |
| Earning Date | 05-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 0.57 | ★ 21.77 |
| EPS | ★ 8.84 | N/A |
| Revenue | $7,806,816,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $5.37 | $9.36 |
| Revenue Next Year | $4.50 | $15.43 |
| P/E Ratio | $20.56 | ★ N/A |
| Revenue Growth | 1.24 | ★ 4.29 |
| 52 Week Low | $147.39 | $22.28 |
| 52 Week High | $221.81 | $59.55 |
| Indicator | WSM | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 34.62 |
| Support Level | $174.75 | $23.52 |
| Resistance Level | $206.37 | $55.36 |
| Average True Range (ATR) | 6.01 | 2.87 |
| MACD | -1.58 | -1.00 |
| Stochastic Oscillator | 1.79 | 13.14 |
With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the nearly $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (152 stores) offers high-end cooking essentials, while Pottery Barn (183) provides casual home accessories. West Elm (120) is an emerging concept for young professionals, and Rejuvenation (13) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (45) as well as Mark & Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.